CO2021004019A2 - Vacunas peptídicas - Google Patents
Vacunas peptídicasInfo
- Publication number
- CO2021004019A2 CO2021004019A2 CONC2021/0004019A CO2021004019A CO2021004019A2 CO 2021004019 A2 CO2021004019 A2 CO 2021004019A2 CO 2021004019 A CO2021004019 A CO 2021004019A CO 2021004019 A2 CO2021004019 A2 CO 2021004019A2
- Authority
- CO
- Colombia
- Prior art keywords
- cancer
- polypeptides
- treatment
- pharmaceutical compositions
- peptides
- Prior art date
Links
- 229940023041 peptide vaccine Drugs 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/828—Stomach
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
La descripción se refiere a polipéptidos y composiciones farmacéuticas que comprenden polipéptidos que encuentran utilidad en la prevención o el tratamiento del cáncer, en particular cáncer gástrico, cáncer de pulmón, melanoma y cáncer de vejiga. La descripción también se refiere a métodos para inducir una respuesta de linfocitos T citotóxicos en un sujeto o tratar un cáncer administrando composiciones farmacéuticas que comprenden los péptidos, y a métodos de diagnóstico complementarios para identificar sujetos para el tratamiento. Los péptidos comprenden epítopos de linfocitos T que son inmunogénicos en un porcentaje alto de pacientes.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1814367.7A GB201814367D0 (en) | 2018-09-04 | 2018-09-04 | Peptide Vaccines |
GBGB1814366.9A GB201814366D0 (en) | 2018-09-04 | 2018-09-04 | Peptide vaccines |
GBGB1814364.4A GB201814364D0 (en) | 2018-09-04 | 2018-09-04 | Peptide vaccines |
GBGB1814365.1A GB201814365D0 (en) | 2018-09-04 | 2018-09-04 | Peptide vaccines |
PCT/EP2019/073476 WO2020048990A1 (en) | 2018-09-04 | 2019-09-03 | Peptide vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021004019A2 true CO2021004019A2 (es) | 2021-07-19 |
Family
ID=67874441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0004019A CO2021004019A2 (es) | 2018-09-04 | 2021-03-30 | Vacunas peptídicas |
Country Status (15)
Country | Link |
---|---|
US (2) | US11666644B2 (es) |
EP (1) | EP3846845A1 (es) |
JP (1) | JP2021536487A (es) |
KR (1) | KR20210086612A (es) |
CN (1) | CN113329761A (es) |
AU (1) | AU2019334437A1 (es) |
BR (1) | BR112021004071A2 (es) |
CA (1) | CA3110760A1 (es) |
CL (1) | CL2021000532A1 (es) |
CO (1) | CO2021004019A2 (es) |
IL (1) | IL281224A (es) |
MA (1) | MA53543A (es) |
MX (1) | MX2021002449A (es) |
SG (1) | SG11202101888YA (es) |
WO (1) | WO2020048990A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3054861A1 (en) | 2017-03-03 | 2018-09-07 | Treos Bio Zrt | Peptide vaccines |
CN113329761A (zh) | 2018-09-04 | 2021-08-31 | 特雷斯生物有限公司 | 肽疫苗 |
AU2022270361A1 (en) | 2021-05-05 | 2023-11-16 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
JP2001504799A (ja) | 1996-03-11 | 2001-04-10 | エピミューン インコーポレイテッド | Hla分子への結合アフィニティーが増加したペプチド |
US6617434B1 (en) | 1996-05-31 | 2003-09-09 | North Shore Long Island Jewish Research Institute | Identificiaton of differentially methylated and mutated nucleic acids |
US20030148463A1 (en) | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
US7227002B1 (en) | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
AU768834B2 (en) | 1998-04-01 | 2004-01-08 | Yale University | A method for selectively modulating the interactions between survivin and tubulin |
FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
AUPQ776100A0 (en) | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
US6673580B2 (en) | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
US20040180354A1 (en) | 2002-09-06 | 2004-09-16 | Simard John J.L. | Epitope sequences |
GB0228900D0 (en) | 2002-12-11 | 2003-01-15 | Ml Lab Plc | Cancer Immunotherapy |
EP1618127B1 (en) | 2003-04-10 | 2014-12-10 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic composition comprising a spike protein of the SARS coronavirus |
US20050100883A1 (en) | 2003-11-12 | 2005-05-12 | Wang Chang Y. | Peptide-based diagnostic reagents for SARS |
PL2087904T3 (pl) | 2003-11-19 | 2014-01-31 | Survac Aps | Zastosowanie terapeutyczne peptydów pochodzących z białek BcL-XL u pacjentów z rakiem |
KR20060129393A (ko) | 2004-01-20 | 2006-12-15 | 아이치 프레펙츄러 | HLA-A2402-제한 Ep-CAM 특이적 CTL에인식되는 에피토프/펩티드 및 그 용도 |
CA2566506A1 (en) | 2004-06-01 | 2005-12-15 | Innogenetics N.V. | Peptides for inducing a ctl and/or htl response to hepatitis c virus |
US20080206270A1 (en) | 2004-07-08 | 2008-08-28 | Minev Boris R | Enhancing Class I Antigen Presentation With Synthetic Sequences |
CN101103108B (zh) | 2005-01-25 | 2011-07-27 | 日本电气株式会社 | Hla-结合肽,和编码所述hla-结合肽的dna片段以及重组载体 |
EP2329840A1 (en) | 2005-02-04 | 2011-06-08 | Survac ApS | Survivin peptide vaccine |
CN100402554C (zh) | 2005-02-25 | 2008-07-16 | 李玉新 | 睾丸特异性蛋白50人源抗体的制备及用途 |
FR2891462B1 (fr) | 2005-09-30 | 2009-10-16 | Commissariat Energie Atomique | Epitopes t cd4+ de la survivine et leurs applications |
GB0520067D0 (en) | 2005-10-01 | 2005-11-09 | Cancer Rec Tech Ltd | Treatment of cancer |
EP1996232B1 (en) | 2006-03-01 | 2016-04-06 | Janssen Pharmaceutica N.V. | CANCER TREATMENT COMBINING LYMPHODEPLETING AGENT WITH CTLs AND CYTOKINES |
EP2089423B1 (en) | 2006-09-21 | 2016-10-26 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope vaccines |
US8129184B2 (en) | 2006-09-26 | 2012-03-06 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
BRPI0720342A2 (pt) | 2006-10-04 | 2018-09-18 | Janssen Pharmaceutica N.V. | preparado de células apresentadoras de antígenos artificiais e seu uso em terapias celulares. |
US8309096B2 (en) * | 2007-01-15 | 2012-11-13 | Glaxosmithkline Biologicals S.A. | Fusion protein |
EP2361930A3 (en) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
EP2042600A1 (en) | 2007-09-28 | 2009-04-01 | Commissariat A L'energie Atomique | A public and immunogenic CD4+ T Cell epitope of the hiv tat protein and its applications |
KR101648146B1 (ko) | 2008-03-31 | 2016-08-16 | 텔라 가부시키가이샤 | Mhc 클래스 ⅱ 분자에 제시되는 서바이빈의 부분 펩타이드 및 그의 용도 |
SI2119726T2 (en) | 2008-05-14 | 2018-03-30 | Immatics Biotechnologies Gmbh | New and powerful Class II MHC peptides derived from survivin and neurocane |
TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
EP2337795A2 (en) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
US20120244145A1 (en) | 2009-11-16 | 2012-09-27 | Duke University | Enhanced immunological responses |
US20170039314A1 (en) | 2010-03-23 | 2017-02-09 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
WO2012051282A2 (en) | 2010-10-14 | 2012-04-19 | The Ohio State University Research Foundation | Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy |
BR112013023978B1 (pt) | 2011-03-21 | 2021-09-08 | Atlantic Cancer Research Institute | Polipeptídeo com afinidade por proteínas de choque térmico e seu uso em diagnóstico de doença infecciosa, produção de resposta imune e tratamento de câncer, bem como ácido nucleico, composição e método de fracionamento de substância para pesquisa ou análise clínica de amostra biológica |
CA2898474A1 (en) | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd. | Cancer vaccines and vaccination methods |
WO2014127276A1 (en) | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd. | Ovarian cancer vaccines and vaccination methods |
ES2886999T3 (es) | 2013-03-27 | 2021-12-21 | Immunovaccine Technologies Inc | Procedimiento para mejorar la eficacia de una vacuna de survivina en el tratamiento de cáncer |
WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
WO2015143335A1 (en) | 2014-03-20 | 2015-09-24 | The University Of North Carolina At Chapel Hill | Methods and compositions for chimeric coronavirus spike proteins |
US10111948B2 (en) | 2014-04-25 | 2018-10-30 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
EP3193892A4 (en) | 2014-09-14 | 2018-09-12 | Washington University | Personalized cancer vaccines and methods therefor |
US20160074489A1 (en) | 2014-09-15 | 2016-03-17 | Regen Biopharma, Inc | Stimulation of immunity to tumor specific and endothelial specific proteins by in vivo dc attraction and maturation |
WO2016090177A1 (en) | 2014-12-03 | 2016-06-09 | Verik Bio, Inc. | Identification, selection and use of high curative potential t cell epitopes |
JP2018509384A (ja) | 2015-01-06 | 2018-04-05 | イミューノヴァクシーン テクノロジーズ インコーポレイテッドImmunovaccine Technologies Inc. | リピドa模倣体、調製方法、及びその使用 |
EP3286361A4 (en) | 2015-04-23 | 2019-05-08 | Nantomics, LLC | CANCER NEO-EPITOPES |
GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
JP6851983B2 (ja) | 2015-05-01 | 2021-03-31 | イミューノヴァクシーン テクノロジーズ インコーポレイテッドImmunovaccine Technologies Inc. | デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法 |
US11090332B2 (en) | 2015-05-21 | 2021-08-17 | Regen BioPharma, Inc. | Antigen specific mRNA cellular cancer vaccines |
MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
US9790562B2 (en) | 2015-09-30 | 2017-10-17 | Augusta University Research Institute, Inc. | Compositions and methods for the detection or treatment of uterine leiomyosarcoma |
AU2016339035A1 (en) | 2015-10-12 | 2018-05-10 | Nantomics, Llc | Systems, compositions, and methods for discovery of MSI and neoepitopes that predict sensitivity to checkpoint inhibitors |
US11160861B2 (en) | 2015-11-18 | 2021-11-02 | Immunovaccine Technologies Inc. | Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvant |
GB201604755D0 (en) * | 2016-03-21 | 2016-05-04 | Vaxeal Res Sas | Immunogenic compositions |
EP3455630A4 (en) | 2016-05-13 | 2020-01-08 | MBL International Corp. | PEPTIDE EXCHANGE SYSTEM AND METHOD |
AU2017338911B2 (en) * | 2016-10-07 | 2021-09-30 | Board Of Regents, The University Of Texas System | HLA-restricted VGLL1 peptides and use thereof |
WO2018102585A1 (en) | 2016-11-30 | 2018-06-07 | Advaxis, Inc. | Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations |
TWI796314B (zh) * | 2017-01-27 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物 |
EP3369431A1 (en) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Vaccine |
CA3054861A1 (en) | 2017-03-03 | 2018-09-07 | Treos Bio Zrt | Peptide vaccines |
EP3370065A1 (en) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Immunogenic peptides |
EP3651733A4 (en) | 2017-07-10 | 2021-04-07 | ImmunoVaccine Technologies Inc. | PHARMACEUTICAL COMPOSITIONS, METHOD OF MANUFACTURING USING LIPID VESICLE PARTICLES OF DEFINED SIZE, AND USES THEREOF |
CA3081710A1 (en) | 2017-11-08 | 2019-05-16 | Advaxis, Inc. | Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof |
EP3706713A4 (en) | 2017-11-09 | 2021-06-16 | ImmunoVaccine Technologies Inc. | PHARMACEUTICAL COMPOSITIONS, METHOD OF MANUFACTURING THEREOF, INCLUDING SIZING OF LIPID VESICLE PARTICLES, AND USES |
JP2021508475A (ja) * | 2017-12-28 | 2021-03-11 | グリットストーン オンコロジー インコーポレイテッド | 共有抗原を標的とする抗原結合タンパク質 |
WO2019222762A1 (en) | 2018-05-18 | 2019-11-21 | Children's National Medical Center | Improved cell therapy compositions for hematopoietic stem cell transplant patients |
JP2021526365A (ja) | 2018-05-18 | 2021-10-07 | チルドレンズ ナショナル メディカル センターChildren’S National Medical Center | 改善された標的化t細胞療法 |
GB201814361D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Immunogenetic cancer screening test |
GB201814362D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Composition and process for preparing vaccine |
CN113329761A (zh) | 2018-09-04 | 2021-08-31 | 特雷斯生物有限公司 | 肽疫苗 |
US20220125903A1 (en) | 2018-11-19 | 2022-04-28 | Immunovaccine Technologies Inc. | Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors |
CA3126066A1 (en) | 2019-01-07 | 2020-07-16 | Children's National Medical Center | Ex vivo activated t-lymphocytic compositions and methods of using the same |
CA3126064A1 (en) | 2019-01-07 | 2020-07-16 | Children's National Medical Center | Improved targeted t-cell therapy for treatment of multiple myeloma |
CN114727957A (zh) | 2019-10-16 | 2022-07-08 | 免疫疫苗技术公司 | 用于递送活性剂或治疗剂的水包油乳剂制剂 |
CN110713546B (zh) | 2019-10-31 | 2021-04-20 | 中国医科大学附属第一医院 | 靶向survivin-XIAP复合物的抗肿瘤多肽Sur-X与用途 |
GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
-
2019
- 2019-09-03 CN CN201980071002.0A patent/CN113329761A/zh active Pending
- 2019-09-03 MX MX2021002449A patent/MX2021002449A/es unknown
- 2019-09-03 SG SG11202101888YA patent/SG11202101888YA/en unknown
- 2019-09-03 MA MA053543A patent/MA53543A/fr unknown
- 2019-09-03 EP EP19765218.3A patent/EP3846845A1/en active Pending
- 2019-09-03 CA CA3110760A patent/CA3110760A1/en active Pending
- 2019-09-03 KR KR1020217009977A patent/KR20210086612A/ko active Search and Examination
- 2019-09-03 JP JP2021512904A patent/JP2021536487A/ja active Pending
- 2019-09-03 AU AU2019334437A patent/AU2019334437A1/en active Pending
- 2019-09-03 WO PCT/EP2019/073476 patent/WO2020048990A1/en active Application Filing
- 2019-09-03 US US17/250,725 patent/US11666644B2/en active Active
- 2019-09-03 BR BR112021004071-4A patent/BR112021004071A2/pt unknown
-
2021
- 2021-03-03 IL IL281224A patent/IL281224A/en unknown
- 2021-03-04 CL CL2021000532A patent/CL2021000532A1/es unknown
- 2021-03-30 CO CONC2021/0004019A patent/CO2021004019A2/es unknown
-
2023
- 2023-05-02 US US18/311,117 patent/US20240000911A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112021004071A2 (pt) | 2021-06-01 |
US11666644B2 (en) | 2023-06-06 |
KR20210086612A (ko) | 2021-07-08 |
CN113329761A (zh) | 2021-08-31 |
WO2020048990A1 (en) | 2020-03-12 |
JP2021536487A (ja) | 2021-12-27 |
SG11202101888YA (en) | 2021-03-30 |
AU2019334437A1 (en) | 2021-03-18 |
IL281224A (en) | 2021-04-29 |
MX2021002449A (es) | 2021-08-05 |
US20230102031A1 (en) | 2023-03-30 |
US20240000911A1 (en) | 2024-01-04 |
EP3846845A1 (en) | 2021-07-14 |
CA3110760A1 (en) | 2020-03-12 |
MA53543A (fr) | 2021-07-14 |
CL2021000532A1 (es) | 2021-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019010698A2 (es) | Vacunas de peptidos | |
CO2021004019A2 (es) | Vacunas peptídicas | |
CO2021004028A2 (es) | Proceso para la preparación de composiciones de vacunas | |
AR104812A1 (es) | Combinaciones terapéuticas y métodos para tratar neoplasias | |
CR20190376A (es) | Formulaciones de anticuerpos de her2 subcutáneas | |
CL2018003699A1 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva (divisional solicitud 201701110) | |
MX353165B (es) | Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13. | |
EA202090751A3 (ru) | Новый метод иммунотерапии нескольких видов опухолевых заболеваний крови, таких как острый миелоидный лейкоз (омл) | |
AR108889A1 (es) | Combinaciones para el tratamiento del cáncer | |
DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
CO2020005485A2 (es) | Administración oral de análogos del péptido glp-1 | |
MX2016014826A (es) | Conjugados de peptido-curcumina y formulaciones de los mismos. | |
EA202090319A1 (ru) | Пептидные конъюгаты, способ конъюгации и их использование | |
NZ730708A (en) | Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof | |
HRP20200160T1 (hr) | Peptidi desmogleina 3 za pemphigus vulgaris | |
CL2021001479A1 (es) | Péptido; uso de composiciones; composición farmacéutica; uso de un anticuerpo para terapia; uso de un anticuerpo para elisa, inmunohistoquímica y/o formación de imágenes; receptor de linfocito t; y uso de un linfocito t citotóxico activado (divisional de la solicitud n° 201701391) | |
EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
AR102555A1 (es) | Inmunoterapia t específica de múltiples péptidos terapéuticos para el tratamiento de metástasis cerebral | |
BR112017007364A2 (pt) | composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico | |
EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
BR112017002206A2 (pt) | peptídeo derivado de koc1 e vacina incluindo o mesmo | |
WO2018013855A3 (en) | Il-15/il-15 receptor alpha treatment regimens and use with therapeutic vaccines | |
EA202190670A1 (ru) | Пептидные вакцины | |
BR112017002212A2 (pt) | peptídeo derivado de cdca1 e vacina contendo o mesmo | |
CL2018002438A1 (es) | Método y composición para el tratamiento del cáncer o una lesión de la piel utilizando una vacuna. |